Exelixis, Inc. is a oncology-focused biopharmaceutical company that discovers, develops, and commercializes cancer treatments. The company's key marketed product is cabozantinib, sold under the brand names Cabometyx and Cometriq, approved for renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Exelixis also has a pipeline of additional oncology compounds in clinical development.
Q2 FY2026 — expected 2026-08-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-10 | 2026-01-02 | 0000939767-26-000021 | EDGAR | 46K words |
| 2025-02-11 | 2025-01-03 | 0000939767-25-000019 | EDGAR | — |
| 2024-02-06 | 2023-12-29 | 0000939767-24-000028 | EDGAR | — |
| 2023-02-07 | 2022-12-30 | 0000939767-23-000019 | EDGAR | — |
| 2022-02-18 | 2021-12-31 | 0000939767-22-000026 | EDGAR | — |
| 2021-02-11 | 2021-01-01 | 0001628280-21-001852 | EDGAR | — |
| 2020-02-25 | 2020-01-03 | 0000939767-20-000035 | EDGAR | — |
| 2019-02-22 | 2018-12-28 | 0000939767-19-000042 | EDGAR | — |
| 2018-02-26 | 2017-12-29 | 0000939767-18-000023 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-10-03 | 0000939767-25-000128 | EDGAR | 26K words |
| 2025-07-28 | 2025-07-04 | 0000939767-25-000113 | EDGAR | — |
| 2025-05-13 | 2025-04-04 | 0000939767-25-000075 | EDGAR | — |
| 2024-10-29 | 2024-09-27 | 0000939767-24-000150 | EDGAR | — |
| 2024-08-06 | 2024-06-28 | 0000939767-24-000119 | EDGAR | — |
| 2024-04-30 | 2024-03-29 | 0000939767-24-000058 | EDGAR | — |
| 2023-11-01 | 2023-09-29 | 0000939767-23-000114 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0000939767-23-000079 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000939767-23-000048 | EDGAR | — |
| 2022-11-01 | 2022-09-30 | 0000939767-22-000110 | EDGAR | — |
| 2022-08-09 | 2022-07-01 | 0000939767-22-000097 | EDGAR | — |
| 2022-05-10 | 2022-04-01 | 0000939767-22-000058 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-10 | 0000939767-26-000019 | EDGAR | 5K words |
| 2026-01-12 | 0000939767-26-000003 | EDGAR | — |
| 2025-11-07 | 0000939767-25-000133 | EDGAR | — |
| 2025-11-04 | 0000939767-25-000127 | EDGAR | — |
| 2025-08-29 | 0000939767-25-000115 | EDGAR | — |
| 2025-07-28 | 0000939767-25-000111 | EDGAR | — |
| 2025-06-02 | 0000939767-25-000097 | EDGAR | — |
| 2025-05-13 | 0000939767-25-000074 | EDGAR | — |
| 2025-03-31 | 0000939767-25-000049 | EDGAR | — |
| 2025-02-21 | 0000939767-25-000032 | EDGAR | — |
139 total filings indexed. 108 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000939767 |
| Ticker | EXEL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.exelixis.com |
| Listed | 2000-04-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report